1. Citadel Precision Medicine is proud to announce a memorandum of understanding (MOU) with the renowned breast cancer specialist and oncologist Dr. B. D. Koppikar (PCCM-Prashanthi Cancer Care Clinic, Pune, India) and Dr. Madhura Kulkarni, Centre for Translation Research, IISER, Pune, India.

• Therapy area: Breast Cancer
• Subtype: Triple Negative Breast Cancer (TNBC)
• Broad objective: Characterization of TME and TIME
• Data modality: Transcriptome & Clinical
• Software: TIMECART

2. Citadel Precision Medicine is delighted to share that the first service and collaboration contract has been established with Dr. Jyoti Kode, Kode Lab, TATA-ACTRE, Mumbai, India.

• Therapy area: Oral cavity cancers and AML
• Cancer types: Tongue and buccal mucosa (Oral) and AML
• Broad objective: Characterization of TME and TIME
• Data modality: Transcriptome & Clinical
• Software: TIMECART

3. These collaborations with clinicians, oncologists & scientists, and their esteemed organizations demonstrate the need for TIMECART software for TME and TIME characterization and allied services in hospitals to support the cancer care continuum. It also substantiates TIMECART-based analysis in research laboratories for the basic and translation outcomes.

4. CPM is privileged to have TIMECART models, analytics & outcomes validated using real-world data provided by our collaborators. The outcomes of these studies will be published jointly.

Citadel News

Citadel Information Services (CIS) Inc. announces an expansion of the organization into Precision Medicine and Healthcare. The new venture of CIS, Citadel Precision Medicine (CPM) aspires to leverage and deliver on the promise of Precision data-driven approaches and advanced technologies to influence the design and development of targeted therapies for patients afflicted by cancer, genetic disorders and rare diseases.

Precision medicine analytics have the ability to detect the early onset and subsequent progression of disease, positively impacting the market potential of pharmaceutical products for chronic, and rare diseases and genetic disorders. Moreover, precision medicine strategies extensively benefit patients and healthcare systems through tailored and better treatments for life threatening diseases that further promotes global market expansion aligned to the commercial pursuits of Pharma and Biotech organizations.

Precision medicine is beginning to make an impact on the treatment of different diseases, but there are still challenges that must be overcome, such as the complexity of interventions, the need for marker validation, and the level of evidence necessary to demonstrate effectiveness. In an effort to address these challenges, CPM’s initiatives are constructed on a foundation of Science, Discovery and Real-World Healthcare experiences. CPM’s 3 cornerstones, viz; Global Health Networks, Global Insights and Global Health Equity, are oriented towards leveraging seminal insights from patient and healthcare journeys, medical expertise and foundational semantic knowledgebases, to transform the treatment recommendations and healthcare delivery to patients in need.

CPM’s enterprise technology framework addresses the challenges of design and recommendation of targeted treatments and healthcare solutions, using multifaceted, phenomenological, quantitative multi-modal data and non-orthogonal AI/ML-driven analytical methods to inform Precision Medicine & Healthcare. CPM will also strive to provision Health Equity in the form of data-driven insights, risk-assessment tools and educational content to patients, providers, payers and other stakeholders. Our ambition and aspiration, is to influence the practice of healthcare and deliver the right medicine to the right patient at the right time, adhering to FAIR & ALCOA principles among other standards at all times.
Through our new venture, we seek to leverage interoperable data and digital technologies, build strategic partnerships and facilitate health equity, to deliver Precision Medicine & Healthcare to patients globally.